Endocrine News
16 articles in the TruthFoundry index. Each links out to the original.
- FDA Approves Rasonque for Pancreatic Cancer and Mounjaro for Cardiovascular Risk · FDA approved Rasonque for metastatic pancreatic cancer and Mounjaro to reduce cardiovascular risk in type 2 diabetes.
- Endocrine Society Supports Bipartisan House Bill Capping Insulin Costs at $35 · The Endocrine Society praised the introduction of the INSULIN Act, a bipartisan bill capping out-of-pocket insulin costs at $35.
- Bradley Anawalt, MD, Honored as Endocrine Society's 2026 Outstanding Educator Laureate · Bradley David Anawalt, MD, receives the 2026 Outstanding Educator Laureate Award for his contributions to medical education and andrology.
- U-Shaped Testosterone Levels Linked to Higher Atrial Fibrillation Risk in Men · A review indicates both low and high testosterone levels increase atrial fibrillation risk in men.
- Study at ENDO 2026 Links Semaglutide to Fewer Bone Fractures in Type 2 Diabetes · Research presented at ENDO 2026 associated semaglutide with lower fracture rates and greater BMI reduction in type 2 diabetes patients.
- Endocrine Society Joins Rally for Medical Research to Urge Congress to Boost NIH Funding · Endocrine Society to join September 17 Rally for Medical Research urging $51.3 billion NIH funding.
- Endo 2026 Highlights GLP-1 Advances, Resilience Amid Funding Cuts · Endo 2026 conference in Chicago showcased GLP-1 progress and endocrinologist resilience despite budget challenges.
- Endocrine Society Reflects on AI, Rising Stars, and Obesity Research at ENDO 2026 · Endocrine News reviews key sessions from ENDO 2026 in Chicago, highlighting AI in endocrinology, rising star winners, and obesity treatment discussions.
- Brittany Weisbrot Wins Endocrine Society Rising Star Clinical Science Award · Brittany Weisbrot won the Clinical Science award at the 2026 Rising Star Power Talks for her research on insulin autoimmune syndrome.
- Menopausal Hormone Therapy Reduces Low Bone Density Risk by 69% in New Study · Research presented at ENDO 2026 shows menopausal hormone therapy reduces low bone mineral density risk by 69%.
- Konstantinos Stefanakis Wins ENDO Rising Star Audience Choice Award · Konstantinos Stefanakis receives the Audience's Choice award at the 2026 ENDO Rising Star Power Talks for his research on MASLD.
- Postnatal Hypothyroidism Causes Developmental Delays and Metabolic Disorders in Mice · A study in Endocrinology finds transient maternal hypothyroidism disrupts male mouse development and metabolism.
- Amylyx Announces Positive Phase 3 Results for Avexitide in Post-Bariatric Hypoglycemia · Amylyx Pharmaceuticals reports positive topline results from the LUCIDITY Phase 3 trial for avexitide in treating post-bariatric hypoglycemia.
- Lila Dabill Wins 2026 Rising Star Power Talks Basic Science Award · Washington University PhD student Lila Dabill wins Basic Science award for Sarm1 obesity research
- Study Links Phthalate Exposure to High Blood Pressure in Pregnant Women · A study suggests phthalates in personal care products may contribute to elevated blood pressure during pregnancy.
- Endocrine Society and Keystone Symposia Partner for Scientific Meeting Series · Two scientific organizations are launching a series of meetings to explore intersections of hormone signaling and disease.